| Literature DB >> 15109535 |
Young Joo Min1, Je-Hwan Lee, Seong-Jun Choi, Hyun-Sook Chi, Jung-Shin Lee, Woo-Kun Kim, Kyoo-Hyung Lee.
Abstract
We analyzed the clinical significance of the expression of the Fas (CD95) and TNF-related apoptosis-inducing ligand (TRAIL) receptors, the death receptors (DR) 4 and 5, by leukemic blasts in 29 patients with acute myelogenous leukemia (AML). CD95 was positive in 18 patients (62%). The DR4 and DR5 receptors were positive in 20 patients (69%) and 29 (100%), respectively. CD95 positivity was not correlated with cytogenetic abnormalities. Complete remission (CR) rate was not significantly different according to the expression of the CD95 or TRAIL receptors. Relapse-free survival was significantly prolonged in patients with CD95-positive AML cells compared with patients with CD95-negative AML cells (73% versus 38% at 3 years; P = 0.047). TRAIL receptors did not show correlation with other clinical parameters.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15109535 DOI： 10.1016/j.leukres.2003.08.015
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156